199 related articles for article (PubMed ID: 38346958)
1. Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer.
Dash S; Ueda T; Komuro A; Honda M; Sugisawa R; Okada H
Cell Death Dis; 2024 Feb; 15(2):131. PubMed ID: 38346958
[TBL] [Abstract][Full Text] [Related]
2. MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
Dash S; Ueda T; Komuro A; Amano H; Honda M; Kawazu M; Okada H
Mol Cancer Res; 2023 May; 21(5):444-457. PubMed ID: 36757299
[TBL] [Abstract][Full Text] [Related]
3. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.
Maity G; Ghosh A; Gupta V; Haque I; Sarkar S; Das A; Dhar K; Bhavanasi S; Gunewardena SS; Von Hoff DD; Mallik S; Kambhampati S; Banerjee SK; Banerjee S
Mol Cancer Ther; 2019 Apr; 18(4):788-800. PubMed ID: 30787177
[TBL] [Abstract][Full Text] [Related]
4. dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.
Xiong J; Altaf K; Ke N; Wang Y; Tang J; Tan C; Li A; Zhang H; He D; Liu X
Medicine (Baltimore); 2016 Mar; 95(10):e2936. PubMed ID: 26962792
[TBL] [Abstract][Full Text] [Related]
5. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer.
Hu Q; Qin Y; Xiang J; Liu W; Xu W; Sun Q; Ji S; Liu J; Zhang Z; Ni Q; Xu J; Yu X; Zhang B
Cell Prolif; 2018 Aug; 51(4):e12456. PubMed ID: 29701272
[TBL] [Abstract][Full Text] [Related]
6. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
Costantino CL; Witkiewicz AK; Kuwano Y; Cozzitorto JA; Kennedy EP; Dasgupta A; Keen JC; Yeo CJ; Gorospe M; Brody JR
Cancer Res; 2009 Jun; 69(11):4567-72. PubMed ID: 19487279
[TBL] [Abstract][Full Text] [Related]
7. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
Saiki Y; Yoshino Y; Fujimura H; Manabe T; Kudo Y; Shimada M; Mano N; Nakano T; Lee Y; Shimizu S; Oba S; Fujiwara S; Shimizu H; Chen N; Nezhad ZK; Jin G; Fukushige S; Sunamura M; Ishida M; Motoi F; Egawa S; Unno M; Horii A
Biochem Biophys Res Commun; 2012 Apr; 421(1):98-104. PubMed ID: 22490663
[TBL] [Abstract][Full Text] [Related]
8. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
9. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
McAllister F; Pineda DM; Jimbo M; Lal S; Burkhart RA; Moughan J; Winter KA; Abdelmohsen K; Gorospe M; Acosta Ade J; Lankapalli RH; Winter JM; Yeo CJ; Witkiewicz AK; Iacobuzio-Donahue CA; Laheru D; Brody JR
Cancer Biol Ther; 2014 Jun; 15(6):688-98. PubMed ID: 24618665
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
Sebastiani V; Ricci F; Rubio-Viqueira B; Kulesza P; Yeo CJ; Hidalgo M; Klein A; Laheru D; Iacobuzio-Donahue CA
Clin Cancer Res; 2006 Apr; 12(8):2492-7. PubMed ID: 16638857
[TBL] [Abstract][Full Text] [Related]
11. Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL).
Hawkins HJ; Yacob BW; Brown ME; Goldstein BR; Arcaroli JJ; Bagby SM; Hartman SJ; Macbeth M; Goodspeed A; Danhorn T; Lentz RW; Lieu CH; Leal AD; Messersmith WA; Dempsey PJ; Pitts TM
PLoS One; 2024; 19(4):e0298808. PubMed ID: 38598488
[TBL] [Abstract][Full Text] [Related]
12. CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy.
Liu ZD; Shi YH; Xu QC; Zhao GY; Zhu YQ; Li FX; Ma MJ; Ye JY; Huang XT; Wang XY; Xu X; Wang JQ; Zhao W; Yin XY
Cancer Lett; 2024 Mar; 585():216640. PubMed ID: 38290659
[TBL] [Abstract][Full Text] [Related]
13. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation.
Ju HQ; Gocho T; Aguilar M; Wu M; Zhuang ZN; Fu J; Yanaga K; Huang P; Chiao PJ
Mol Cancer Ther; 2015 Mar; 14(3):788-98. PubMed ID: 25527634
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
[TBL] [Abstract][Full Text] [Related]
16. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
Vena F; Bayle S; Nieto A; Quereda V; Aceti M; Frydman SM; Sansil SS; Grant W; Monastyrskyi A; McDonald P; Roush WR; Teng M; Duckett D
Mol Cancer Ther; 2020 Aug; 19(8):1623-1635. PubMed ID: 32430484
[TBL] [Abstract][Full Text] [Related]
17. Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer.
Masoud R; Reyes-Castellanos G; Lac S; Garcia J; Dou S; Shintu L; Abdel Hadi N; Gicquel T; El Kaoutari A; Diémé B; Tranchida F; Cormareche L; Borge L; Gayet O; Pasquier E; Dusetti N; Iovanna J; Carrier A
Cell Rep Med; 2020 Nov; 1(8):100143. PubMed ID: 33294863
[TBL] [Abstract][Full Text] [Related]
18. Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
Funamizu N; Okamoto A; Kamata Y; Misawa T; Uwagawa T; Gocho T; Yanaga K; Manome Y
Oncol Rep; 2010 Feb; 23(2):471-5. PubMed ID: 20043109
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
